Aim: Describe a patient with multiple recurrences of the primary recurrent liposarcoma. Clinical case: A 60-years-old man complained of weight loss (BMI 18.4) with a palpable huge retroperitoneal tumour, which displaced left kidney, and was confi rmed on USG and CT. Laboratory examination showed anaemia and pathological blood tests. Chest X-ray initially showed a negative fi nding. A complete transperitonealy surgical extirpation of the tumour with left side nephrectomy was performed on June 28, 2007. The tumour mass weight was 1900 g. It was lying on the posterior face of the kidney in diameters 170x120x120 mm, completely capsulated by thin grey-pink capsula with peripheral fat tissue on the section grey-pink, lobulary shaped, in ¾ parts with central necrotic changes. Histopathologically was confi rmed the primary dedifferentiated (non-lipogenous) liposarcoma low grade of malignancy. Nephrectomy specimen was confi rmed as age related fi nding. There was no evidence of positives surgical margins. Despite oncological and surgical treatment, followed repeated recurrence with eight transperitoneal surgeries in the retroperitoneum and abdomen with extirpation of the metastases, left side hemicolectomy, splenectomy and repeated extirpation tumour metastases from abdomen and radix mesenterii. Last tumour weighed 2900 grams. Patient died on January 9, 2011, after the eight surgeries on multiorgans failure due to hemorrhagic shock and persistent atrial fi brilaton by cardiopulmonary insuffi ciency. As a speciality, he was treated without transfusion because as Jehovah´s witness he refused blood derivates. Conclusion: Despite complex surgical and oncological treatment, the prognosis in patient with recurrent liposarcoma was fatal (Tab. 1, Fig. 5 Retroperitoneal liposarcoma is an infrequent locally aggressive and recurrent malignancy developed from mesenchymal tissue. We report a seldom case of a huge primary retroperitoneal liposarcoma on the left side, which invaded and displaced the left kidney with multicentric intraperitoneal and retroperitoneal repeated recurrences, adjuvant chemotherapy and eight surgeries.
Retroperitoneal liposarcoma is an infrequent locally aggressive and recurrent malignancy developed from mesenchymal tissue. We report a seldom case of a huge primary retroperitoneal liposarcoma on the left side, which invaded and displaced the left kidney with multicentric intraperitoneal and retroperitoneal repeated recurrences, adjuvant chemotherapy and eight surgeries.
Case presentation
The 60-years old man complained of weight loss 10 kg in three month (weight 52 kg, hight168 cm, BMI: 18.4) with some vague symptoms. Physical examination revealed a palpable abdominal mass on the left side. Preoperative USG and CT imaging study showed a huge retroperitoneal tumour. On USG examination, there was seen a clear burdened hypoechoic retroperitoneal mass. CT on June 20, 2007 demonstrated on the left side retroperitoneal tumour 167x124x119 mm, a slightly heterogenous mass with native density +22 to +31 HU, and postcontrast enhancement from +29 to +58 and + 60 HU. Tumour invaded and displaced the left kidney without hydronephrosis (Fig. 1) . Laboratory data showed anaemia and pathological blood tests (Hb11,5 dg/l, RBC 3,91x10 12 /l, PVC 0,34, WBC 15,6x10 9 /l, Tr 426 000, N 87% seg, Eo 2%, Mo 3%, Ly 8%, elevated Fibrinogen 8, 55 (N 1.8-3.5 g/l), FW 88/fi rst hour). S-Na140 mmol/l, S-K 4,0 mmol/l, S-Cl 104 mmol/l, S-Creatinine 52,3 μmol/l, GMT 0,64, ALP 2,87, PSA 1,01 ng/ml were within normal limits. Chest X-ray showed initially a negative fi nding without metastasis (MTS). A complete transperitonealy surgical extirpation of the tumour with left side nephrectomy without adrenalectomy was performed on June 28, 2007. The tumour mass weighted 1900 g. Macroscopically the tumour was lying on the posterior face of the kidney with diameters 170x120x120 mm and was completely capsulated by thin grey-pink capsula with peripheral fat tissue (Fig. 2) . On the section, the tumour was grey-pink, lobulary shaped, in ¾ parts with central necrotic changes. Histopathologically, tumour was confi rmed as dedifferentiated liposarcoma (non-lipogenous) low grade of malignancy; nephrectomy specimen was histologically confi rmed as age related fi nding. There was no evidence of positive surgical margins. After oncologist consultation, he received postoperatively no adjuvant therapy. CT three months later on October 3, 2007 showed no MTS. February 11, 2008 on haematology examination was established diagnosis of heterozygous MTHFR congenital thrombophilia without elevation homocystein acids, hyperuricemia, hepatopathia wits elevation ALP, defi ciency of vitamin K depending factors and Factor VIII, and sideropenia. On February 20, 2008 , eight months later, CT confi rmed fi rst retroperitoneal MTS on the left side which were resected on March 7, 2008 (Fig. 3) . Similarly, CT on October 10, 2008 showed recurrence of a new MTS nearby m. psoas and colon descendens. Followed extirpation of this tumour on October 28, 2008. On November 2, 2009 due to new MTS, left hemicolectomy with tumour extirpation was done. Because recurrence of the liposarcoma continued, the surgical treatment was performed on March 3, 2010. During this surgery, multiplices MTS were found on radix mesenterii and also completely extirpated (Fig. 4) . Followed operations on April 8, 2010, then on June 15, 2010, and finally on December 28, 2010 because of excessive huge recurrence in the whole left part of the abdoment and retroperitoneum with tumour weight 2900 grams (Fig. 5) . The position of this metastasis was the same as the fi rst time surgical resected tumour in year 2007. Patient died on January 9, 2011, after the eight surgeries on multiorgans failure due to hemorrhagic shock and persistent atrial fi brilaton and cardiopulmonary insuffi ciency. As a speciality, he 
Discussion
With their embryological origin in the mesoderm and in nerve structures of the neuroectodermic layer soft tissue, sarcomas represent only 1.5 % cases in the National Registry of Malignant Tumours in Mexico (Pérez-Ponce et al, 2008). Liposarcoma is a malignancy of fat cells and is the most frequent soft tissue sarcoma localized in the retroperitoneum often with multicentric origin (Sato et al, 2004) . Retroperitoneal sarcoma is a rare tumour that accounts for 10-15 % of soft tissue malignancies. The incidence is 2.5 per million and liposarcoma accounts for approximately 20 % of all retroperitoneal sarcomas. As a slow-growing tumour with vague symptoms, the most frequent symptom is nonspecifi c abdominal pain, sometimes anorexia, loss weight and diffuse abdominal enlargement, but rarely it was presented by another symptoms, e.g. lower gastrointestinal bleeding or hemoperitoneum, with a picture of acute abdomen resulting from a massive tumour haemorrhage (Wanchik et (Funahashi et al, 2004 ), or well-differentiated liposarcoma of the retroperitoneum and spermatic cord, contiguous through the inguinal canal was presented clinically as a scrotal mass (Longbotham and Joyce, 1987) . In literature are reported extremely rare cases of paraneoplastic syndromes or ectopic production of proteins associated with liposarcoma, as a production of Granulocyte-Colony Stimulating Factor, alpha-fetoprotein, paraneoplastic pemphigus and leucocytosis, Acrokeratosis paraneoplastica (Bazex´s syndrome) or cases of retroperitoneal liposarcoma associated with small plaque parapsoriasis (Tartaglia et al, 2007) . Liposarcoma can occur in the extremities with unusual pattern of metastatic spread (Vassilopoulos et al, 2001 ).
If we used the words "abdominal and retroperitoneal liposarcoma" for searching in Pubmed, we have found more than 70 articles with this topic from 1954 to June 22, 2011. Many of them described a case report or small series on a huge retroperitoneal or abdominal liposarcoma in both, men and women. In some cases, tumour mass occupies the whole retroperitoneum, pelvis and part of the abdomen. Sometimes can reach substantial proportions ( As the fi rst preoperative imaging study, except history and physical examination, was used USG, sometimes with incidentally founding of the liposarcoma, but the best diagnostic tool before surgery in decisive majority was mainly CT, or MRI, with histological confi rmation during or after surgery (Shoji et The histological subtype and margins of resection are the most important prognostic factors for survival in primary retroperitoneal liposarcoma. Sato et al (1999) described nine primary intra-abdominal or retroperitoneal liposarcoma, of which eight were recurrent tumours. Histopathological examination of primary tumours revealed that the number of well-differentiated, pleomorphic and myxoid type was two, four and three respectively. In two recurrent cases, histological differentiation changed from well-differentiated type into myxoid or pleomorphic types. It was seen also by other authors. Spindle cell liposarcoma is presently regarded as a rare variant of well-differentiated liposarcoma, which has the potential for aggressive clinical behaviour (Shioi et al. 2010 ). Dedifferentiated histological subtype and the need for contiguous organ resection was associated with an increase risk of local and distant recurrence. Nephrectomy may be needed to achieve complete resection, but has no infl uence on disease specifi c survival. Singer et al (2003) in a prospective database identifi ed 177 patients with primary liposarcoma operated on for curative intent. Of them 99 (56 %) presented with well-differentiated, 65 (37 %) with dedifferentiated, 9 (5 %) with myxoid, and 4 (2 %) with round cell morphology. Multivariate analysis showed that dedifferentiated liposarcoma subtype was associated with a 6-fold increased risk of death compared with well-differentiated histology (p<0.0001). In addition to histological subtype, incomplete resection (p<0.0001), contiguous organ resection (excluding nephrectomy; p=0.05), and age (p=0.03) were important independent prognostic factors for survival in retroperitoneal liposarcoma.
The only accepted treatment is a wide surgical excision with clear margins, without a clear benefi t for adjuvant treatment. The very uncommon nature of these tumours and their varied histopathology, site and behaviour classify them as a diffi cult entity in terms of treatment (Pérez-Ponce et al, 2008). Since neoadjuvant and adjuvant therapy as well as intraoperative radiotherapy failed to prove prognostic value, curative resection remains the main treatment for primary and recurrent liposarcomas (Niedergethmann et al, 2001 ). The main problem after surgery is local or distant recurrence. Local recurrences are frequent, especially in the fi rst three years, often in the absence of distant metastases. Farma et al (2003) in 4 patients for retroperitoneal liposarcoma performed 15 operations, in 4 patients a second operation was performed for recurrence, in 3 a third operation and in 1 a fourth. Fotiadis et al (2000) described two patients in whose tumour recurred 5 times. In our patient, we have done eight surgeries. When the tumour recurs locally, the best therapy is still to remove the mass. In the treatment of liposarcoma the conventional chemotherapy does not seem effective, while radiotherapy has a little improvement on survival. Generally, the prognosis was poor with overall 5-year survival of 15-50 % (Lauretti et al, 1998) . Yoshida et al (2007) in a 58-year-old woman after resection of giant retroperitoneal liposarcoma and the transverse colon, spleen, and the left kidney with disease recurrence initially unsuccessfully used mesna, doxorubicin, ifosfamide, and dacarbazine therapy (MAID). Despite this chemotherapy disease progressed, and patient developed oedema in the bilateral legs due to inferior vena cava (IVC) compression. Then they started weekly paclitaxel therapy (100 mg/m 2 ), once a week for 3 weeks followed by 1 drug-free week. CT revealed no change as the result of chemotherapy; however, IVC compression had improved, and leg oedema had decreased. She died 11 month later after starting paclitaxel therapy. Yokoi et al (2009) in a 53-year-old patient after surgery with multiple unresectable abdominal metastases histologically proven as dedifferentiated, and well-differentiated liposarcoma unsuccessfully used as a fi rst-line VAC (VCR 1.5 mg, ACD 0.5 mg, CPA 900 mg) chemotherapy with disease progression. As second-line chemotherapy, weekly IFM (2g)+CDDP (30 mg) was given. A partial response against peritoneal dissemination was achieved. However, hepatic metastases increased, and the patient died 6 months after surgery. They concluded, that this case suggested that IFM+CDDP might be useful in dedifferentiated liposarcoma. Baratti et al (2010) assessed the outcome of clinically and pathologically homogenous subsets of 37 patients with peritoneal sarcomatosis, from which 13 patients had retroperitoneal liposarcoma (RPLP), uniformly treated by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin and doxorubicin or mitomycin-C. Overall, the results of CRS and HIPEC did not compare favorably to those of conventional therapy. In a subgroup analysis, the combined approach did not change RPLP natural history. In our patient, the progression of the malignant diseases continued despite third-line chemotherapy, and patient developed new metastases. Also, our case showed multiple recurrences and surgeries and unsuccessful adjuvant chemotherapy with limited survival. As review of literature showed, curative resection remains the main treatment for primary and recurrent liposarcomas. No standardized guidelines have been established for its treatment because too small series of the patients have been reported and surgical resection was considered by all authors as the treatment of choice. Some success on the fi eld of the adjuvant chemotherapy must be proven by well controlled, blinded, randomized studies.
Conclusion
Primary retroperitoneal liposarcoma is a serious malignancy without standardized treatment. This diseases to prejudice QoL because multiple surgeries and unsuccessful adjuvant therapy with unpleasant consequences for patients. Curative resections remains the main treatment for primary and recurrent liposarcomas, and the best therapy is still to remove the mass. Surgical treatment of the primary recurrent liposarcoma without effective adjuvant oncological therapy had limited effectivity.
